vs
AETHLON MEDICAL INC（AEMD）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是AETHLON MEDICAL INC的13781.9倍（$826.4M vs $60.0K）。GLOBUS MEDICAL INC净利率更高（17.0% vs -2926.4%，领先2943.4%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-2.0M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
AEMD vs GMED — 直观对比
营收规模更大
GMED
是对方的13781.9倍
$60.0K
净利率更高
GMED
高出2943.4%
-2926.4%
自由现金流更多
GMED
多$204.4M
$-2.0M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $826.4M |
| 净利润 | $-1.8M | $140.6M |
| 毛利率 | — | 68.4% |
| 营业利润率 | -3026.4% | 20.5% |
| 净利率 | -2926.4% | 17.0% |
| 营收同比 | — | 25.7% |
| 净利润同比 | 49.4% | 430.4% |
| 每股收益（稀释后） | $-10.05 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDGMED
| Q4 25 | — | $826.4M | ||
| Q3 25 | — | $769.0M | ||
| Q2 25 | — | $745.3M | ||
| Q1 25 | — | $598.1M | ||
| Q4 24 | $60.0K | $657.3M | ||
| Q3 24 | $95.1K | $625.7M | ||
| Q2 24 | — | $629.7M | ||
| Q1 24 | — | $606.7M |
净利润AEMDGMED
| Q4 25 | — | $140.6M | ||
| Q3 25 | — | $119.0M | ||
| Q2 25 | — | $202.8M | ||
| Q1 25 | — | $75.5M | ||
| Q4 24 | $-1.8M | $26.5M | ||
| Q3 24 | $-2.8M | $51.8M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $-7.1M |
毛利率AEMDGMED
| Q4 25 | — | 68.4% | ||
| Q3 25 | — | 67.2% | ||
| Q2 25 | — | 66.6% | ||
| Q1 25 | — | 67.3% | ||
| Q4 24 | — | 59.9% | ||
| Q3 24 | — | 56.8% | ||
| Q2 24 | — | 58.7% | ||
| Q1 24 | — | 60.2% |
营业利润率AEMDGMED
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 10.2% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | -3026.4% | 9.2% | ||
| Q3 24 | -3050.2% | 7.7% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 1.3% |
净利率AEMDGMED
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | -2926.4% | 4.0% | ||
| Q3 24 | -2950.2% | 8.3% | ||
| Q2 24 | — | 5.0% | ||
| Q1 24 | — | -1.2% |
每股收益（稀释后）AEMDGMED
| Q4 25 | — | $1.01 | ||
| Q3 25 | — | $0.88 | ||
| Q2 25 | — | $1.49 | ||
| Q1 25 | — | $0.54 | ||
| Q4 24 | $-10.05 | $0.19 | ||
| Q3 24 | $-16.11 | $0.38 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $557.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3M | $4.6B |
| 总资产 | $6.5M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AEMDGMED
| Q4 25 | — | $557.2M | ||
| Q3 25 | — | $18.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.8M | $890.1M | ||
| Q3 24 | $6.9M | $71.9M | ||
| Q2 24 | — | $82.5M | ||
| Q1 24 | — | $80.4M |
股东权益AEMDGMED
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.3B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | $4.3M | $4.2B | ||
| Q3 24 | $6.0M | $4.1B | ||
| Q2 24 | — | $4.0B | ||
| Q1 24 | — | $3.9B |
总资产AEMDGMED
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | $6.5M | $5.3B | ||
| Q3 24 | $8.8M | $5.1B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $4.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $202.4M |
| 自由现金流率自由现金流/营收 | -3357.0% | 24.5% |
| 资本支出强度资本支出/营收 | 3.7% | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | — | $588.8M |
8季度趋势，按日历期对齐
经营现金流AEMDGMED
| Q4 25 | — | $248.6M | ||
| Q3 25 | — | $249.7M | ||
| Q2 25 | — | $77.9M | ||
| Q1 25 | — | $177.3M | ||
| Q4 24 | $-2.0M | $210.3M | ||
| Q3 24 | $-2.2M | $203.7M | ||
| Q2 24 | — | $54.3M | ||
| Q1 24 | — | $52.4M |
自由现金流AEMDGMED
| Q4 25 | — | $202.4M | ||
| Q3 25 | — | $213.9M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | — | $141.2M | ||
| Q4 24 | $-2.0M | $193.2M | ||
| Q3 24 | — | $161.7M | ||
| Q2 24 | — | $26.5M | ||
| Q1 24 | — | $23.8M |
自由现金流率AEMDGMED
| Q4 25 | — | 24.5% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 23.6% | ||
| Q4 24 | -3357.0% | 29.4% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 4.2% | ||
| Q1 24 | — | 3.9% |
资本支出强度AEMDGMED
| Q4 25 | — | 5.6% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | 3.7% | 2.6% | ||
| Q3 24 | 0.0% | 6.7% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 4.7% |
现金转化率AEMDGMED
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEMD
暂无分部数据
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
